opioids, compared to a 4 mg dose of IN naloxone. Model simulations were performed using a validated translational model1 developed by the Division of Applied Regulatory Science in the US Food and Drug Administration's Center for Drug Evaluation and...
BioMarin Pharmaceutical Inc. announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increases in bone length...
and pharmaceutical industries, has partnered with Polestar Technologies, a leader in optical sensing technologies since 1993, specializing in the monitoring of O2, CO2 and pH. Qosina is pleased to announce the addition of iDOT Single-Use Sensor Bag...
themselves with senescent cells, with negative correlations between the amount of senescent cells and patient survival1. Furthermore, increased resistance to cancer therapies such as chemotherapy2, radiation therapy3, and immunotherapy4 is...
which can continue to cause neuronal injury. The sBLA is based on modeling of observed data from the Phase 2 study (Study 201) and its open-label extension (OLE) as well as the Clarity AD study (Study 301) and its OLE study. Alzheimer's disease is...
of ALK5. Agomab is evaluating AGMB-447 as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) in a Phase 1 clinical trial (NCT06181370). The FDA's Orphan Drug Designation program is designed to facilitate development of medicinal...
on the question of whether the available data show that midomafetamine is effective in patients with PTSD. They also voted 1 yes to 10 no on the question of whether the benefits of midomafetamine with FDA's proposed risk evaluation and mitigation...
completion that supports significantly improved productivity. Compared to traditional technologies, Stellar MS achieves 10X the quantitative sensitivity while analyzing five times more compounds for proteomics, metabolomics, and lipidomics....
fits on a bench-top. The neofleX Imaging Profiler MALDI-TOF/TOF mass spectrometer comes standard with Bruker’s proprietary 10 kHz smartbeam 3D laser for true pixel fidelity and with enhanced imaging detectors designed for longitudinal robustness,...
included achievement of EAS / ESC LDL-C targets, and other lipid and apolipoproteins changes. Patients were randomized 2:1 to a single 300 mg once-monthly, subcutaneous dose of Lerodalcibep or placebo for 52 weeks. Approximately 85% of participants...
leading global spine and orthopedics company, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Rodeo™ Telescopic Nail. The Rodeo Telescopic Nail is an innovative device indicated to...
Company ("Tabuk"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in key regions of...
volume without increasing collection time. The clinical trial to support the recent FDA clearance showed an average 10% increase in the volume of plasma collected per donation with an average collection time of less than 35 minutes.2 The Terumo BCT...
Ingredients (HPAPIs). ONFAB prides itself on high standards of customer service and manufacturing and is ISO 9001 accredited. the internationally recognized standard for an organization's internal quality management. For more information please...
of the standard of care treatment paradigm for multiple myeloma and prolongs survival for patients with this cancer type.1 Historically, depending on induction regimens and mobilization strategies, approximately 50% to 75% of patients required more...
after review of all available safety data, the Company initiated screening of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300...
Drug (IND) application for ADRX-0706 which enables the company to include China-based clinical centers in the ongoing Phase 1a/1b study for the treatment of select advanced solid tumors. ADRX-0706 is an ADC comprised of a novel fully human IgG1...
non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation. The presentation, "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive...
a significant patient treatment milestone for the most prevalent bleeding disorder in the United States. VWD affects up to 1% of the U.S. population, including many who are undiagnosed. "The FDA orphan exclusivity is exciting news for Octapharma...
as they continue to expand their offerings under the Aurora brand. The dried flower products are available now in four 10g formats including: "This expanded offering aims to serve patients with more choice, novel cultivars and expertly grown...